File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome

TitleSignificance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome
Authors
Issue Date2011
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal of Hepatology, 2011, v. 55 n. 3, p. 522-528 How to Cite?
AbstractBACKGROUND and AIMS: The significance of early HBV DNA suppression during telbivudine treatment in predicting long-term outcomes needs further investigation. METHODS: We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (<12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients (61.5% HBeAg-positive) on telbivudine for 3years. The significance of serum HBV DNA at week 12 and 24 was compared. RESULTS: The median age and duration of follow-up were 39years and 24.2months, respectively. 117, 105, 69, and 43 patients had been followed up for at least 6months and 1, 2, and 3years, respectively. The cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA undetectability were 46.8%, 80.5%, and 51.2%, respectively, at 3years. There was an incremental increase in virologic breakthroughs to 39.5% by year 3. The cumulative rate of telbivudine resistant mutations was 4.8%, 17.6%, and 34.0% for year 1, 2, and 3, respectively. Week 12 HBV DNA of <200IU/ml was predictive of a higher chance of HBV DNA undetectability (p=0.022) and lower chance of resistance (p=0.001) by year 3. Undetectable HBV DNA at week 24 was predictive of viral suppression at year 2 (p<0.001) but not at year 3 (p=0.241). CONCLUSIONS: Continuous telbivudine resulted in improved biochemical and virologic outcomes, although there was an incremental increase in cumulative rate of resistance up to year 3. Week 12 HBV DNA of <200IU/ml was predictive of favorable long-term outcomes.
Persistent Identifierhttp://hdl.handle.net/10722/137383
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorFung, Jen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorHung, IFNen_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2011-08-26T14:24:12Z-
dc.date.available2011-08-26T14:24:12Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal of Hepatology, 2011, v. 55 n. 3, p. 522-528en_HK
dc.identifier.issn0168-8278en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137383-
dc.description.abstractBACKGROUND and AIMS: The significance of early HBV DNA suppression during telbivudine treatment in predicting long-term outcomes needs further investigation. METHODS: We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (<12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients (61.5% HBeAg-positive) on telbivudine for 3years. The significance of serum HBV DNA at week 12 and 24 was compared. RESULTS: The median age and duration of follow-up were 39years and 24.2months, respectively. 117, 105, 69, and 43 patients had been followed up for at least 6months and 1, 2, and 3years, respectively. The cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA undetectability were 46.8%, 80.5%, and 51.2%, respectively, at 3years. There was an incremental increase in virologic breakthroughs to 39.5% by year 3. The cumulative rate of telbivudine resistant mutations was 4.8%, 17.6%, and 34.0% for year 1, 2, and 3, respectively. Week 12 HBV DNA of <200IU/ml was predictive of a higher chance of HBV DNA undetectability (p=0.022) and lower chance of resistance (p=0.001) by year 3. Undetectable HBV DNA at week 24 was predictive of viral suppression at year 2 (p<0.001) but not at year 3 (p=0.241). CONCLUSIONS: Continuous telbivudine resulted in improved biochemical and virologic outcomes, although there was an incremental increase in cumulative rate of resistance up to year 3. Week 12 HBV DNA of <200IU/ml was predictive of favorable long-term outcomes.en_HK
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_HK
dc.relation.ispartofJournal of Hepatologyen_HK
dc.subject.meshAntiviral Agents - therapeutic use-
dc.subject.meshHepatitis B virus - genetics-
dc.subject.meshHepatitis B, Chronic - blood - drug therapy - virology-
dc.subject.meshNucleosides - pharmacology - therapeutic use-
dc.subject.meshPyrimidinones - pharmacology - therapeutic use-
dc.titleSignificance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcomeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0168-8278&volume=55&issue=3&spage=522&epage=528&date=2010&atitle=Significance+of+HBV+DNA+levels+at+12+weeks+of+telbivudine+treatment+and+the+3+years+treatment+outcome-
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailYuen, JCH: jchyuen@hkucc.hku.hken_HK
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jhep.2010.11.018en_HK
dc.identifier.pmid21147187-
dc.identifier.scopuseid_2-s2.0-84860390069en_HK
dc.identifier.hkuros189850en_US
dc.identifier.hkuros211251-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84860390069&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume55en_HK
dc.identifier.issue3en_HK
dc.identifier.spage522en_HK
dc.identifier.epage528en_HK
dc.identifier.isiWOS:000293930600006-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridHung, IFN=55202074600en_HK
dc.identifier.scopusauthoridYuen, JCH=7102620480en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.citeulike8451348-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats